The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands

Psychopharmacology

Volumn 124, Issue 3, 1996, Pages 245-254

  Griebel, Guy ^a   Sanger, David J ^a   Perrault, Ghislaine ^a  

^a SANOFI   (France)

Author keywords

Anxiety; Benzodiazepines; BZ 1 ( 1) receptor; Elevated plus maze; Locomotor activity; Rat; Risk assessment

Indexed keywords

3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ABECARNIL; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE 1 RECEPTOR; BENZODIAZEPINE 1 RECEPTOR AGONIST; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRETAZENIL; CHLORDIAZEPOXIDE; CLORAZEPATE; DIAZEPAM; IMIDAZENIL; PARTIAL AGONIST; RO 19 8022; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG DISCRIMINATION; DRUG SELECTIVITY; ETHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ALPRAZOLAM; ANIMALS; ANTI-ANXIETY AGENTS; CHLORDIAZEPOXIDE; DIAZEPAM; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 0029933404     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246664     Document Type: Article

References (52)

1. Auta J, Romeo E, Kozikowski A, Ma D, Costa E, Guidotti A (1993) Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3-indoleacetamide and imidazopyridine derivatives. J Pharmacol Exp Ther 265: 649-656
2. Belzung C, Misslin R, Vogel E (1989) Behavioural effects of the benzodiazepine receptor partial agonist RO 16-6028 in mice. Psychopharmacology 97:388-391
3. Blanchard DC, Blanchard RJ, Tom P, Rodgers RJ (1990a) Diazepam changes risk assessment in an anxiety/defense test battery. Psychopharmacology 101:511-518
4. Blanchard DC, Rodgers RJ, Blanchard RJ (1990b) Ethopharmacological control of fear and anxiety in the rat. In: Brain PF, Parmigiani F, Blanchard RJ, Mainardi D (eds) Fear and defence. Harwood Academic Publishers, London, pp 245-267
5. Cole JC, Rodgers RJ (1993) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav Pharmacol 4:573-580
6. Cole JC, Rodgers RJ (1994) Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 114:288-296
7. Cruz APM, Frei F, Graeff FG (1994) Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49:171-176
8. Davies MF, Onaivi ES, Chen S-W, Maguire PA, Tsai NF, Loew GH (1994) Evidence for central benzodiazepine receptor heterogeneity from behavior tests. Pharmacol Biochem Behav 49: 47-56
9. Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD (1995) Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 118: 316-323
10. Day IP, Clody DE, Monaghan MM, Abel MS, Dusza JP, Beer B (1992) Pharmacology of CL 284,846, a non-benzodiazepine sedative with reduced amnestic liability. Soc Neurosci Abstr 18:725
11. A receptor modulators. J Pharmacol Exp Ther 273:241-247
12. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G (1986) Zolpidem, a novel non-benzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649-658
13. A receptor. Eur J Pharmacol 246:283-287
14. File SE (1992) Behavioural detection of anxiolytic action. In: Elliott JM, Heal DJ, Marsden CA (eds) Experimental approaches to anxiety and depression. John Wiley, Chichester, pp 25-44
15. A receptors. J Pharmacol Exp Ther 266:1018-1028
16. Griebel G, Belzung C, Misslin R, Vogel E (1993) The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav Pharmacol 4:637-644
17. Griebel G, Moreau J-L, Jenck F, Misslin R, Martin JR (1994) Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113:463-470
18. Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995) A model of "antipredator" defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 7:732-745
19. Haefely W, Martin JR, Schoch P (1990) Novel anxiolytics that acts as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 11:452-456
20. Handley SL, McBlane JW (1993) An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods 29:129-138
21. Jenck F, Moreau JL, Bonetti EP, Martin JR, Haefely WE (1992) Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic. J Pharmacol Exp Ther 262:1121-1127
22. Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ, Stephens DN (1994) Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies. Psychopharmacology 114:191-199
23. A receptor. J Pharmacol Exp Ther 266:385-391
24. Lader M (1994) Benzodiazepines: a risk-benefit profile. CNS Drugs 1:377-387
25. Langer SZ, Arbilla S (1988) Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as ω receptor subtypes. Pharmacol Biochem Behav 29:763-766
26. Lippa AS, Coupet J, Greenblatt EN, Klepner CA, Beer B (1979) A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety. Pharmacol Biochem Behav 11:99-106
27. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185
28. Martin JR, Pieri L, Bonetti EP, Schaffner R, Burkard WP, Cumin R, Haefely WE (1988) Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 21:360-362
29. Martin JR, Schoch P, Jenck F, Moreau J-L, Haefely WE (1993) Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero. Psychopharmacology 111:415-422
30. Ozawa M, Nakada Y, Sugimachi K, Yabuuchi F, Akai T, Mizuta E, Kuno S, Yamaguchi M (1994) Pharmacological characterization of the novel anxiolytic β-carboline abecarnil in rodents and primates. Jpn J Pharmacol 64:179-187
31. Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525-529
32. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167
33. Potokar J, Nutt DJ (1994) Anxiolytic potential of benzodiazepine receptor partial agonists. CNS Drugs 1:305-315
34. 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 54:1802-1804
35. A-benzodiazepine receptors produced in transfected cells. Science 245:1389-1392
36. Puia G, Ducic I, Vicini S, Costa E (1992) Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at γ-aminobutyric acid type A receptor. Proc Natl Acad Sci USA 89:3620-3624
37. Rodgers RJ, Cole JC (1993) Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors. Physiol Behav 53:383-388
38. Rodgers RJ, Cole JC, Cobain MR, Daly P (1992a) Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 3:621-634
39. Rodgers RJ, Lee C, Shepherd JK (1992b) Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 106:102-110
40. Sanger DJ (1995) The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol 6:116-126
41. Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B (1991) Animal models of anxiety and the development of novel anxiolytic drugs. Prog Neuropsychopharmacol Biol Psychiatry 15: 205-212
42. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994) Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 18:355-372
43. A receptor subtypes. Pharmacol Rev 47:181-234
44. Sieghart W, Schuster A (1984) Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Biochem Pharmacol 33:4033-4038
45. Squires RF, Benson DI, Braestrup C, Coupet J, Klepner CA, Myers V, Beer B (1979) Some properties of brain specific ben/odiazepine receptors: new evidence for multiple receptors. Pharmacol Biochem Behav 10:825-830
46. Stephens DN, Voet B (1994) Differential effects of anxiolytic and non-anxiolytic benzodiazepine receptor ligands on performance of a differential reinforcement of low rate (DRL) schedule. Behav Pharmacol 5:4-14
47. Stephens DN, Schneider HH, Kehr W, Andrews JS, Rettig KJ, Turski L, Schmiechen R, Turner JD, Jensen LH, Petersen EN et al. (1990) Abecarnil, a metabolically stable, anxioselective β-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 253:334-343
48. Treit D (1985) Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 9:203-222
49. Treit D, Menard J, Royan C (1993) Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44:463-469
50. Wafford KA, Whiting PJ, Kemp JA (1993) Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant γ-aminobutyric acid receptor subtypes. Mol Pharmacol 43: 240-244
51. Zivkovic B, Morel E, Joly D, Perrault G, Sanger DJ, Lloyd KG (1990) Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry 23 [Suppl 3]: 108-113
52. Zivkovic B, Perrault G, Sanger D (1992) Receptor subtype-selective drugs: a new generation of anxiolytics and hypnotics. In: Mendlewitz J, Racagni G (eds) Target receptors for anxiolytics and hypnotics: from molecular pharmacology to therapeutics. Karger, Basel, pp 55-73